

This is a repository copy of *Long-term major adverse cardiovascular events following myocardial injury after non-cardiac surgery: meta-analysis*.

White Rose Research Online URL for this paper: <u>https://eprints.whiterose.ac.uk/199031/</u>

Version: Published Version

Article:

Strickland, S.S., Quintela, E.M. orcid.org/0000-0001-9367-073X, Wilson, M.J. et al. (1 more author) (2023) Long-term major adverse cardiovascular events following myocardial injury after non-cardiac surgery: meta-analysis. BJS Open, 7 (2). ISSN 2474-9842

https://doi.org/10.1093/bjsopen/zrad021

Reuse

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here: https://creativecommons.org/licenses/

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk https://eprints.whiterose.ac.uk/

Long-term major adverse cardiovascular events following myocardial injury after non-cardiac surgery: meta-analysis

Scarlett S. Strickland¹, Ella M. Quintela^{2,3,*} (D), Matthew J. Wilson^{2,3} and Matthew J. Lee^{1,4} (D)

¹Academic Directorate of General Surgery, Sheffield Teaching Hospitals, Sheffield, UK

²Department of Anaesthesia, Sheffield Teaching Hospitals, Sheffield, UK

³Centre for Urgent and Emergency Care Research, School of Health and Related Research, University of Sheffield, Sheffield, UK

⁴Department of Oncology and Metabolism, The Medical School, University of Sheffield, Sheffield, UK

*Correspondence to: Ella M. Quintela, School of Health and Related Research, University of Sheffield, 30 Regent St, Sheffield, South Yorkshire S1 4DA, UK (e-mail: e.quintela@sheffield.ac.uk)

Abstract

Background: Myocardial injury after non-cardiac surgery is diagnosed following asymptomatic troponin elevation in the perioperative interval. Myocardial injury after non-cardiac surgery is associated with high mortality rates and significant rates of major adverse cardiac events within the first 30 days following surgery. However, less is known regarding its impact on mortality and morbidity beyond this time. This systematic review and meta-analysis aimed to establish the rates of long-term morbidity and mortality associated with myocardial injury after non-cardiac surgery.

Methods: MEDLINE, Embase and Cochrane CENTRAL were searched, and abstracts screened by two reviewers. Observational studies and control arms of trials, reporting mortality and cardiovascular outcomes beyond 30 days in adult patients diagnosed with myocardial injury after non-cardiac surgery, were included. Risk of bias was assessed using the Quality in Prognostic Studies tool. A random-effects model was used for the meta-analysis of outcome subgroups.

Results: Searches identified 40 studies. The meta-analysis of 37 cohort studies found a rate of major adverse cardiac events-associated myocardial injury after non-cardiac surgery of 21 per cent and mortality following myocardial injury after non-cardiac surgery was 25 per cent at 1-year follow-up. A non-linear increase in mortality rate was observed up to 1 year after surgery. Major adverse cardiac event rates were also lower in elective surgery compared with a subgroup including emergency cases. The analysis demonstrated a wide variety of accepted myocardial injury after non-cardiac surgery and major adverse cardiac events diagnostic criteria within the included studies.

Conclusion: A diagnosis of myocardial injury after non-cardiac surgery is associated with high rates of poor cardiovascular outcomes up to 1 year after surgery. Work is needed to standardize diagnostic criteria and reporting of myocardial injury after non-cardiac surgery-related outcomes.

Registration: This review was prospectively registered with PROSPERO in October 2021 (CRD42021283995).

Introduction

Cardiac complications remain a leading cause of postoperative morbidity and mortality^{1,2}. The occurrence of cardiac complications following coronary intervention is well described by the 4th Universal Definition of Myocardial Infarction³. However, there is increasing recognition of myocardial injury following non-cardiac surgery (MINS)⁴. A diagnosis of MINS is made through the presence of elevated cardiac troponin levels, thought to be ischaemic in nature, without associated ischaemic features (for example chest pain or ECG changes), which occur within 30 days of surgery^{2,3,5–7}.

MINS is thought to result from an imbalance in myocardial oxygen supply and demand arising during an acute interval of illness³. The exact mechanism as to how this occurs remains largely unknown. Recent studies suggest that acute postoperative endothelial dysfunction has a role to play⁸, in particular, impaired endothelial nitrous oxide production⁹. Underlying vagal dysfunction, leading to an inability to adapt to the physiological stresses of surgery, has also been suggested as a potential cause of MINS^{10,11}.

MINS may occur following at least 8 per cent of elective procedures^{2,12} and up to 25 per cent of emergency surgery cases¹³. It is associated with increased mortality within 30 days following surgery⁷ as well as longer length of inpatient stay^{2,14}. Furthermore, evidence has emerged to suggest a link between MINS and the occurrence of major adverse cardiac events (MACE). This appears to persist despite controlling for other confounders such as baseline cardiac risk¹⁵. Although there is no universally accepted definition of MACE¹⁶, components frequently reported in studies include myocardial infarction, non-haemorrhagic stroke, arrhythmia, heart failure, peripheral arterial thrombosis, cardiac arrest and amputation^{2,15,17}.

The incidence of MACE following MINS is reported frequently in the first 30 days; however, less is known about the long-term sequelae of MINS². A systematic review in 2020 has highlighted that beyond 1 year after surgery, mortality rates of patients with MINS remain statistically higher than those without the diagnosis¹⁸. Therefore, this systematic review and meta-analysis

Received: September 26, 2022. Revised: December 12, 2022. Accepted: January 27, 2023

 $\ensuremath{\mathbb{C}}$ The Author(s) 2023. Published by Oxford University Press on behalf of BJS Society Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

aims to establish long-term morbidity and mortality rates, in the context of MACE outcomes, in patients diagnosed with MINS.

Methods

This systematic review was reported in line with the PRISMA guidelines¹⁹ and conducted with reference to the Cochrane Handbook and Meta-analyses Of Observational Studies in Epidemiology (MOOSE) guidelines^{20,21}.

A search strategy (*Appendix* S1) was devised by S.S. and M.J.L. with reference to previous reviews regarding MINS^{15,18,22}. Searches of the following electronic databases were conducted in October 2021 via MEDLINE (via OvidSP), Embase (via OvidSP) and Cochrane CENTRAL (1974–2021 with no other limits applied).

All search results were exported onto a software database, Rayyan²³, and duplicates were then removed. Abstracts were screened for inclusion by two reviewers (S.S. and E.Q.) and conflicts resolved by a third (M.J.L.). Full texts were retrieved for included abstracts. Full texts were screened against eligibility criteria and extracted onto a predesigned data extraction sheet created in Microsoft Excel (Microsoft Corporation, Redmond, VA, USA) by two authors (S.S. and E.Q.). This form included study descriptors, type of operation, definition of MINS and MACE, study population with MINS, end time of study and included outcomes at day 30, 60, 90 and 1 year after surgery.

Eligibility criteria

Studies reporting outcomes 30 days or more following surgery in patients who developed myocardial injury after MINS were included. For this study, MINS was defined as any value of troponin reaching a predefined threshold without associated ECG changes.

Only studies involving adult patients (aged 18 years and above) were included. Cohort studies and control arms of interventional studies treating MINS in any non-cardiac surgical setting were considered.

Studies reporting on paediatric patients (aged under 18 years), those who underwent cardiac surgery and patients who were not diagnosed with myocardial injury were excluded. Studies that did not stipulate their diagnostic criteria for MINS were also excluded. Case reports, diagnostic studies and studies reporting on intervention arms of RCTs were also excluded.

Primary outcome

The primary outcome was mortality and any cardiovascular complication within the MACE definition which was defined by the original study. These definitions were also recorded. Where available, aggregate MACE rates and components of MACE were extracted to address heterogeneity between studies that may have variations in reported outcomes. Accepted MACE components include myocardial infarction, non-haemorrhagic stroke, arrhythmia, heart failure, peripheral arterial thrombosis, cardiac arrest, amputation and death. Where available, event rates of mortality and MACE components were documented at 30 days, 60 days, 90 days, 6 months and 1 year.

Qualitative synthesis

For each included study, the definitions used to diagnose myocardial injury and MACE were extracted. Data on event rates were extracted where meta-analysis was not possible.

Statistical analysis and planned subgroup analyses

From baseline data, subgroups were formed based on type of surgery by specialty and acuity of surgery. Planned subgroup analyses were comparison of mortality and MACE events between subgroups. Where three or more studies reported an outcome of interest, the Mantel-Haenszel random-effects approach was used to meta-analyse the proportions with subgroups according to acuity of surgery or type of surgery as appropriate.

Summary event rates were calculated for the whole population and each subgroup, with 95 per cent confidence intervals. If subgroups consisted of studies with differing follow-up intervals, for example when comparing between different types of surgery and acuity, event rates were calculated to events per day. Analyses were conducted using R statistics and the Meta package²⁴.

Bias assessment

Two reviewers (S.S. and E.Q.) assessed each included study for risk of bias using the validated Quality in Prognostic Studies tool (QUIPS)²⁵. QUIPS was selected as the studies used MINS as a risk factor for cardiovascular outcomes. The QUIPS tool was used to assess risk of bias for each included study. Risk of bias was assessed across six domains: study participation, study attrition, prognostic factor, outcome measure, confounding and statistical analysis. Each domain included subheadings to facilitate and standardize the interrater bias assessment²⁶. Disagreements in bias scores were resolved through discussion. No studies were excluded from the analysis based on the results of bias assessment.

Results

A total of 10652 studies were initially identified from searches. Following the removal of duplicates, 7367 abstracts were screened. Screening excluded 7165 abstracts leading to 202 full texts undergoing assessment for eligibility. Based on predefined inclusion and exclusion criteria, 162 studies were excluded resulting in 40 studies being included in the final analysis (Fig. 1).

Study characteristics

A summary of study characteristics is included in Table 1. The majority of studies included all types of non-cardiac surgery in their eligibility criteria^{2,15,22,30,33–35,37,38,40,43,44,46–49,51,56,58,60–62,65}. Seventeen studies focused on specific surgical subspecialties including vascular^{28,39,41,42,45,52–54}, orthopaedic^{29,31,32,50,55,59,64}, urology^{36,63} and thoracic surgery^{36,63}. Regarding surgical acuity, only two studies focused on emergency non-cardiac surgery^{31,32}, whilst nine studies specifically included only patients undergoing elective surgery^{28,35–38,52,53,58,63}.

The length of follow-up for all included studies was recorded in days. Follow-up intervals are summarized in *Table 1* and ranged from 30 to 2555 days, with a median follow-up interval of 365 days. Due to the variety in follow-up intervals, event rates were converted to a per-day rate to allow comparison.

Outcomes reported are summarized in *Table S1*. Thirty five of the 38 included cohort studies reported mortality^{2,22,28–31,33–47}. ^{49,51–55,57,59–64,66}. For MACE rates, myocardial infarction was the most frequently reported outcome (16)^{28,29,31,37,48,50–53,56,57}, ^{59–61,64,65}, followed by heart failure (9)^{2,28,31,37,48,53,56,64,65} and arrhythmia (5)^{31,36,48,56,65}. All three control arms from randomized controlled studies also reported rates of death or



Fig. 1 PRISMA flow diagram of study selection²⁷

MINS, myocardial injury after non-cardiac surgery.

mortality, MACE and myocardial infarction^{15,32,58}. None of the included studies reported outcomes for cardiac arrest or amputation.

Definitions

A summary of the diagnostic criteria used by included studies for MINS is shown in *Table S2*.

Of the included 40 studies, 19 used high-sensitivity troponins to diagnose MINS^{31,32,34–36,38,40,46–49,52,53,56–59,62,64}. Twenty-five studies used troponin I^{22,28–33,35,36,39,40,42–45,48,50,52,53,59–64}, whilst 12 used troponin T assays^{2,34,38,41,46,47,49,51,54,56–58}. Variation was seen between studies regarding sampling frequency, ranging from immediately after surgery to anytime within 30 days of surgery. Eight studies measured troponin preoperatively as well as postoperatively^{31–33,51,56–58,67}. Definitions of MACE used by studies for reporting outcomes are summarized in *Table* S3.

Meta-analysis

Thirty-seven studies were included in the meta-analysis of cohort studies^{2,22,28-31,33-46,50-57,60-64}. *Table* 2 summarizes event rates by

meta-analysis by follow-up interval. Zero studies reporting outcome rates at 60 and 90 days led to these time points being excluded. The numbers of peripheral arterial thrombosis and amputation events were insufficient to permit meta-analysis. *Table 3* summarizes the outcome of meta-analysis of cohort studies for mortality and components of MACE by type of surgery. *Table 4* provides a summary of the meta-analysis of cohort studies for mortality and components of MACE by surgical acuity.

Three control $\operatorname{arms}^{6,32,58}$ were included for analysis with follow-up periods ranging from 30^{58} to 730^{15} days. Event rate analysis was limited to death, MACE and myocardial infarction due to availability of reported outcomes.

Mortality

The meta-analysis of eligible cohort studies demonstrated that the mortality rate associated with MINS sharply increases from 8 per cent (95 per cent c.i. 6–12 per cent) at 6 months^{38,39,42} to 25 per cent at 1 year^{29–31,33,44,49,51,55,57,59–63–64} (95 per cent c.i. 21–30 per cent) (Fig. 2). This increase plateaus towards 38 per cent beyond 2 years (95 per cent c.i. 22–57 per cent)^{41,43,47,53,54} (Table 2).

Table 1 Summary of included studies: study design, surgery type and follow-up interval

Author (year)	Design	Type of surgery	Emergency or elective	Follow-up interval (days)
Ali et al. 2008 ²⁸	Cohort	Vascular	Elective	571
Auroy et al. 2008 ²⁹	Cohort	Orthopaedic	Mix	365
Beattie et al. 2012 ²²	Cohort	Non-cardiac	Mix	30
Botto et al. 2014 ²	Cohort	Non-cardiac	Mix	30
Canbolat et al. 2014 ³⁰	Cohort	Non-cardiac	Not specified	365
Chong et al. 2009 ³¹	Cohort	Orthopaedic	Emergency	365
Chong et al. 2012 ³²	Control arm of RCT	Orthopaedic	Emergency	365
Devereaux et al. 2018 ¹⁵	Control arm of RCT	Non-cardiac	Not specified	730
Filipovic et al. 2003 ³³	Cohort	Non-cardiac	Not specified	365
Genc Moralar et al. 2021 ³⁴	Cohort	Non-cardiac	Mix	30
George et al. 2018 ³⁵	Cohort	Non-cardiac	Elective	30
Gonzalez- Tallada et al. 2020 ³⁶	Cohort	Thoracic	Elective	30
Gouda et al. 2021 ³⁷	Cohort	Non-cardiac	Elective	180
Hallqvist et al. 2016 ³⁸	Cohort	Non-cardiac	Elective	180
Hobbs et al. 2005 ³⁹	Cohort	Vascular	Not specified	180
Jackson et al. 2018 ⁴⁰	Cohort	Non-cardiac	Mix	180
Kertai et al. 2004 ⁴¹	Cohort	Vascular	Not specified	1570
Kim et al. 2002 ⁴²	Cohort	Vascular	Not specified	180
Kim et al. 2016 ⁴³	Cohort	Non-cardiac	Not specified	2555
Kim et al. 2021 ⁴⁴	Cohort	Non-cardiac	Mix	365
Kisten and Biccard 2016 ⁴⁵	Cohort	Vascular	Mix	Not specified
Kler et al. 2021 ⁴⁶	Cohort	Non-cardiac	Not specified	90
Lee et al. 2019 ⁴⁷	Cohort	Non-cardiac	Mix	760
Lee et al. 2020 ⁴⁸	Cohort	Non-cardiac	Mix	30
Mol et al. 2019 ⁴⁹	Cohort	Non-cardiac	Mix	365
Oberweis et al. 2015 ⁵⁰	Cohort	Orthopaedic	Mix	1095
Oscarsson et al. 2004 ⁵¹	Cohort	Non-cardiac	Mix	365
Pereira-Macedo et al. 2019 ⁵²	Cohort	Vascular	Elective	1570
Pereira-Macedo et al. 2020 ⁵³	Cohort	Vascular	Elective	1550
Reed et al. 2017 ⁵⁴	Cohort	Vascular	Not specified	1825
Rostagno et al. 2019 ⁵⁵	Cohort	Orthopaedic	Not specified	365
Sazgary et al. 2020 ⁵⁶	Cohort	Non-cardiac	Mix	365
Szczeklik et al. 2018 ⁵⁷	Cohort	Vascular	Not specified	365
Toda et al. 2020 ⁵⁸	Control arm of RCT	Non-cardiac	Elective	30
Vacheron et al. 2021 ⁵⁹	Cohort	Orthopaedic	Not specified	365
Van Waes et al. 2016 ⁶⁰	Cohort	Non-cardiac	Mix	365
Van Waes et al. 2017 ⁶¹	Cohort	Non-cardiac	Mix	365
Vasireddi et al. 2021 ⁶²	Cohort	Non-cardiac	Not specified	365
Yu et al. 2020 ⁶³	Cohort	Urology	Elective	365
Yuan et al. 2019 ⁶⁴	Cohort	Orthopaedic	Mix	365

The pooled rate of MINS-associated mortality was 0.08 deaths per day (95 per cent c.i. 0.04-0.18) (Fig. 3)^{2,22,28-31,33,35,36,38,39, 41-44,47,49,51,53-55,57,59-64}. This is similar to rates observed from the meta-analysis of control arm studies. These demonstrated a pooled mortality rate of 0.04 (95 per cent c.i. 0.01-0.22) (Fig. 4)^{15,32,58}.

Subgroup analysis by acuity (Fig. 3) demonstrated that elective surgery had a death rate per day of 0.03 (95 per cent c.i. 0.01–0.13)^{28,35,36,38,53,63}. Studies including a mix of emergency and elective cases had a death rate of 0.29 (95 per cent c.i. 0.06–1.35)^{2,22,29,44,49,51,60,61,64}.

With regard to surgical specialties, vascular surgery was associated with a mortality rate of 0.02 (95 per cent c.i. 0.01–0.05) per day^{28,39,41,42,45,57}, whilst the mortality rate for orthopaedic patients was 0.06 (95 per cent c.i. 0.02–0.21) per day^{29,31,55,59,64} (Fig. S1). Similarly, studies reporting all types of non-cardiac surgery^{2,22,30,33,35,38,43,44,47,49,51,60–62} had a death rate of 0.23 (95 per cent c.i. 0.07–0.71) per day. These differences were statistically significant at P < 0.01.

Aggregate MACE

At 1-year follow-up, the proportion of patients experiencing MACE events associated with MINS was 0.21^{49,56,57,63,64} (95 per cent c.i.

0.12–0.34), compared with an overall rate of 0.25 (95 per cent c.i. 0.14–0.39), regardless of follow-up interval^{28,36,49,53,56,57,63,64}.

The meta-analysis of eligible cohort studies showed differing pooled daily MACE rates to control arm studies. A pooled daily rate of $0.05^{28,36,46,49,53,56,57,63,64}$ (95 per cent c.i. 0.02-0.13) (Fig. 5) was demonstrated by the meta-analysis of eligible cohort studies. This was lower in comparison to the control arm studies which showed a MINS-associated MACE daily pooled rate of $0.14^{15,32,58}$ (95 per cent c.i. 0.02-0.93) (Fig. 6).

The MACE rate associated with elective surgery was 0.02 per day (95 per cent c.i. 0.01-0.07)^{28,36,53,63} (Fig. 5). There were no available studies reporting MACE outcomes exclusively in emergency surgery; however, studies with mixed acuity demonstrated a MACE rate of 0.13 per day (95 per cent c.i. 0.03-0.68) (Fig. 5)^{49,56,64}. The difference between these subgroups was statistically significant (P < 0.01).

Vascular surgery-specific studies were eligible for meta-analysis which showed an overall MACE rate of 0.02 (95 per cent c.i. 0.01–0.06) per day (Fig. S2)^{28,53,57}. Studies that had a broader classification of 'non-cardiac' surgery demonstrated a pooled MACE rate of $0.20^{46,49,56}$ (95 per cent c.i. 0.08–0.5). Differences between these two subgroups were statistically significant at P < 0.01 (Fig. S2).

Table 2 Summary table of meta-analysis outcomes for cohort studies by follow-up interval

Event	Follow-up interval									
	Per cent with event at 1 month (95% c.i.)	Per cent with event at 6 months (95% c.i.)	Per cent with event at 1 year (95% c.i.)	Per cent with event at 2 years (95% c.i.)	Per cent with event beyond 2 years (95% c.i.)	Overall event rate pooled result (95% c.i.)				
Death	9 (3 to 24)	8 (6 to 12)	25 (21 to 30)	*	38 (22 to 57)	22 (17 to 28)				
MACE	*	* '	21 (12 to 34)	*	*	25 (14 to 39)				
Arrhythmia	*	*	*	*	*	12 (6 to 22)				
Heart failure	*	*	*	*	*	11 (8 to 16)				
Non-haemorrhagic stroke	*	*	*	*	*	2 (2 to 3)				
Myocardial infarction	*	*	12 (8 to 18)	*	28 (7 to 68)	13 (8 to 20)				

*Inadequate number of studies for meta-analysis. MACE , major adverse cardiac events.

Table 3 Summary table of meta-anal	vsis of cohort studies for mortality	y and components of MACE by type of	of surgery (events per day)
	,	· ····································	

Type of surgery	Death	Overall MACE	Stroke	Arrhythmia	MI	CCI
			Events/day (95%	c.i.)		
Non-cardiac	0.23	0.2	*	*	0.19	*
Vascular	0.02 (0.01–0.05)	0.02	*	*	0.01	*
Orthopaedic	0.046 (0.01–0.05)	*	*	*	0.03 (0.01–0.05)	*
Thoracic	*	*	*	*	*	*
Urology	*	*	*	*	*	*
Pooled	0.08 (0.04–0.18) P <0.01	0.05 (0.02–0.13) P <0.01	0.01 (0.00–0.27) P <0.01	*	0.05 (0.02–0.13) P=0.01	*

*Inadequate number of studies for meta-analysis. MACE, major adverse cardiac events; MI, myocardial infarction; CCF, congestive cardiac failure.

Impact of the use of high-sensitivity troponin

The meta-analysis of studies using high-sensitivity troponin^{31,32,34-36,38,40,46-49,52,53,56-59,62,64} versus other troponins^{2,15,22,28-30,33,37,39,41-45,50,51,54,55,60,61,63} demonstrated pooled mortality rates of 0.19^{31,35,36,38,47,49,52,57,59,62,64} (95 per cent c.i. 0.11–0.29) versus 0.24^{2,22,28-30,33,39,41-45,51,54,55,60,61,63} (95 per cent c.i. 0.18–0.32) respectively, which were significantly different (P < 0.01, $I^2 = 92$ per cent) (Fig. 7). Similarly, the rate of MACE in the non-high-sensitivity troponin group was 0.28^{28,63} (95 per cent c.i. 0.13–0.51) versus 0.20 (95 per cent c.i. 0.10–0.36) for the high-sensitivity troponin group^{36,46,49,53,56,57,64} (P < 0.01, $I^2 = 96$ per cent) (Fig. S3).

Other components of MACE

Further meta-analysis of individual MACE components including myocardial infarction, arrhythmia, heart failure and non-haemorrhagic stroke by follow-up interval is available in *Table 2*. Subgroup analysis by surgical specialty and surgical acuity is detailed in *Tables 3* and 4 respectively. Due to infrequent reporting of arrhythmia and stroke, these outcomes were not suitable for further meta-analyses by subgroups (*Table S1*).

Bias assessment

Bias assessment revealed a majority of low and moderate bias risk across all six domains. High risk of bias was found in four studies^{39,46,60,62}; however, this was confined to study participation in three of the studies^{39,46,62} and attrition in the remaining study⁶⁰. Bias assessments using QUIPS are summarized in *Table* S4.

Discussion

This systematic review and meta-analysis demonstrates that MINS is associated with both a high mortality rate (25 per cent) and a high rate of MACE (21 per cent) at 1 year after surgery. Notably, this review has highlighted the lack of a standardized diagnostic threshold for MINS as well as inconsistent reporting of MACE and other outcome measures for patients who have developed MINS. The findings of this study have implications in both clinical practice and future research.

It is widely accepted that MINS is associated with an increased 30-day mortality², but there has been limited work exploring outcomes beyond 30 days. A systematic review by Smilowitz *et al.*¹⁸ found that mortality at 1 year was four times higher in those who had MINS than those who did not (20 *versus* 5.1 per cent). These findings are consistent with the results of this review, although this review goes further and found the mortality rate associated with MINS continues to increase beyond 2 years after surgery and may approach 31 per cent. Notably, this increase is non-linear and many of the events were detected by 1 year. Whilst further longitudinal studies on the long-term sequelae of MINS are required, 1 year may be the plausible biological causation limit of MINS.

The current study explored mortality associated with MINS and the type of surgery performed, as well as the urgency of the procedure. The analysis showed mortality rates associated with MINS varied between different surgical specialties. For example, patients undergoing orthopaedic surgery had an increased mortality rate of 0.30 per day (95 per cent c.i. 0.24–0.37), whilst the mortality rate for vascular surgery patients was 0.26 (95 per

Table 4 Summary table of me	eta-analysis of cohort studie	es for mortality and com	ponents of MACE by sur	gical acuity (events per day)
,	,	,		5 5 1	1 1/

Surgical acuity	Death	Overall MACE	Stroke	Arrhythmia	MI	CCF
			Events/day	(95% c.i.)		
Mix	0.29 (0.06–1.35)	0.13 (0.03–0.68)	*	*	0.05 (0.02–0.16)	0.04 (0.01–0.27)
Not specified	0.05 (0.03–0.09)	*	*	*	0.04 (0.02–0.10)	*
Elective	0.03 (0.01–0.13)	0.02 (0.01–0.07)	*	*	0.02 (0.00–0.59)	0.03 (0.00–1.65)
Emergency	*	*	*	*	*	*
Pooled	$\begin{array}{c} 0.08\\ (0.04-0.18)\\ P=0.14 \end{array}$	0.05 (0.02–0.13) P < 0.01	0.01 (0.00–0.27) P < 0.01	0.14 (0.03–0.59) P < 0.01	$\begin{array}{c} 0.04 \\ (0.02-0.09) \\ P = 0.70 \end{array}$	0.04 (0.01-0.17) P=0.71

*Inadequate number of studies for meta-analysis of subgroup. MACE, major adverse cardiac events; MI, myocardial infarction; CCF, congestive cardiac failure.

Study	Events	Total		Proportion	95% c.i.
Follow-up period = 1 month					
Botto <i>et al.</i> ²	117	1194	+	0.10	(0.08, 0.12)
Gonzalez-Tallada et al.36	0	48	-	0.00	(0.00, 0.07)
George et al.35	22	188		0.12	(0.07. 0.17)
Beattie et al.22	285	1173	-	0.24	(0.22, 0.27)
Random-effects model		2603	-	0.09	(0.03, 0.24)
Heterogeneity: $\tau^2 = 0.8953$; $P < 0.01$; $I^2 = 97\%$					
Follow-up period = 6 months					
Kim <i>et al.</i> ⁴²	18	229	₩	0.08	(0.05, 0.12)
Hobbs <i>et al</i> . ³⁹	3	11		0.27	(0.06, 0.61)
Hallqvist <i>et al.</i> ³⁸	6	90		0.07	(0.02, 0.14)
Random-effects model		330	•	0.08	(0.06, 0.12)
Heterogeneity: $\tau^2 = 0$; $P = 0.09$; $l^2 = 58\%$					
Follow-up period = 1 year	50			0.00	
	59	211		0.28	(0.22, 0.35)
Mol et al.49	307	1678	—	0.18	(0.16, 0.20)
	17	53		0.32	(0.20, 0.46)
Kim <i>et al.</i> ⁴⁴ data from SMC–TINCO registry	1079	5633		0.19	(0.18, 0.20)
Yu et al. ⁶³	10	35		0.29	(0.15, 0.46)
	100	123		0.06	(0.02, 0.11)
Van waes et al.00	182	/15		0.25	(0.22, 0.29)
Rostagno <i>et al.</i> ⁵⁵	35	92		0.38	(0.28, 0.49)
	155	634		0.24	(0.21, 0.20)
	20	54		0.37	(0.24, 0.51)
	3	11		0.27	(0.06, 0.61)
	12	27		0.44	(0.25, 0.65) (0.14, 0.27)
Szczeklik el al.º' Vuon et al.64	10	26		0.23	(0.14, 0.37) (0.14, 0.45)
Vecheron et al. ⁵⁹	150	604		0.25	(0.14, 0.43)
Pandom offacts model	156	024		0.25	(0.22, 0.23) (0.21, 0.30)
Heterogeneity: $\tau^2 = 0.1928$; $P < 0.01$; $l^2 = 86\%$		9907		0.25	(0.21, 0.30)
Follow-up period = 2 years					
Ali <i>et al.</i> ²⁸	2	20		0.10	(0.01, 0.32)
Follow-up period = > 2 years					
Pereira-Macedo et al.36	10	17		0.59	(0.33, 0.82)
Lee et al.47	14	132	—	0.11	(0.06, 0.17)
Reed <i>et al.</i> ⁵⁴	68	162	·	0.42	(0.34, 0.50)
Kertai <i>et al.</i> 41	22	54		0.41	(0.28, 0.55)
Kim <i>et al.</i> ⁴³	50	92	— <u>—</u>	0.54	(0.44, 0.65)
Random-effects model		457		0.38	(0.22, 0.57)
Heterogeneity: $\tau^2 = 0.6951$; $P < 0.01$; $I^2 = 92\%$					
Random-effects model		13397	•	0.22	(0.17, 0.28)
Heterogeneity: $\tau^2 = 0.6957$; $P < 0.01$; $I^2 = 92\%$					

Fig. 2 Meta-analysis of death reporting in cohort studies with subgroups of follow-up interval

SMC-TINCO registry, Samsung Medical Center Troponin in Non cardiac Operation registry.

Study	Events	Time	•	Incidence rate		Rate	95% c.i.	Weight (%)
Acuity = not specified								
Vasireddi et al.62	59	365	1			0.16	(0.13, 0.21)	3.7
Kim <i>et al.</i> 42	18	180	+			0.10	(0.06, 0.16)	3.6
Canbolat <i>et al.</i> 30	7	365	+			0.02	(0.01, 0.04)	3.6
Reed <i>et al.</i> ⁵⁴	68	1825	+			0.04	(0.03, 0.05)	3.7
Rostagno <i>et al.</i> 55	35	365	+			0.10	(0.07, 0.13)	3.7
Kertai et al.41	22	1570	1			0.01	(0.01, 0.02)	3.6
Hobbs et al.39	3	180	+			0.02	(0.01, 0.05)	3.4
Filipovic <i>et al.</i> ³³	12	365				0.03	(0.02, 0.06)	3.6
Szczeklik <i>et al</i> . ⁵⁷	15	365	+			0.04	(0.02, 0.07)	3.6
Kim <i>et al</i> . ⁴³	50	2555	1			0.02	(0.01, 0.03)	3.7
Vacheron <i>et al.</i> ⁵⁹	158	365	+			0.43	(0.37, 0.51)	3.7
Random-effects model			+			0.05	(0.03, 0.09)	39.9
Heterogeneity: $\tau^2 = 1.1512$; $P < 0.01$; $l^2 = 99\%$								
Acuity = MIX								
Mol et al.49	307	365	+			0.84	(0.75, 0.94)	3.7
Oscarsson <i>et al.</i> ⁵¹	17	365	+			0.05	(0.03, 0.07)	3.6
Kim et al.44 – data from SMC-TINCO registry	1079	365	i.	+		2.96	(2.78, 3.14)	3.7
Lee et al.47	14	760	+			0.02	(0.01, 0.03)	3.6
van Waes <i>et al.</i> 60	182	365	+			0.50	(0.43, 0.58)	3.7
van Waes <i>et al.</i> 61	155	365	+			0.42	(0.36, 0.50)	3.7
Auroy <i>et al</i> . ²⁸	3	365	+			0.01	(0.00, 0.03)	3.4
Yuan <i>et al.</i> ⁶⁴	10	365	+	_		0.03	(0.01, 0.05)	3.6
Botto et al. ²	117	30			_	3.90	(3.25, 4.67)	3.7
Beattie et al. ²²	285	30	i i			9.50	(8.46, 10.67)	3.7
Random-effects model						0.29	(0.06, 1.35)	36.4
Heterogeneity $\tau^2 = 5.9818$; $P = 0$; $I^2 = 100\%$								
Acuity = elective								
Pereira–Macedo et at.36	10	1550	11			0.01	(0.00, 0.01)	3.6
Yu <i>et al.</i> 63	10	365	1			0.03	(0.01, 0.05)	3.6
Ali <i>et al.</i> ²⁸	2	571	1			0.00	(0.00, 0.01)	3.3
Hallqvist <i>et al</i> . ³⁸	6	180	1			0.03	(0.01, 0.07)	3.5
Gonzalez–Tallada <i>et al</i> . ³⁶	0	30	E.			0.02	(0.00, 0.27)	2.5
George <i>et al</i> . ³⁵	22	30	+			0.73	(0.48, 1.11)	3.6
Random-effects model			•			0.03	(0.01, 0.13)	20.1
Heterogeneity: $\tau^2 = 3.5458$; $P < 0.01$; $I^2 = 98\%$			ł					
Acuity = emergency								
Chong et al.31	20	365	1			0.05	(0.04, 0.08)	3.6
Bandom-effects model						0.08	(0.04.0.18)	100.0
Heterogeneity: $\tau^2 = 4.0533 \cdot P = 0 \cdot l^2 = 100\%$			•			0.00	(0.01, 0.10)	100.0
Test for subgroup differences: $\gamma_{2}^{2} = 5.53$, 3 d.f.,	(P = 0.14)	-)		2 4 6	8 10			

Fig. 3 Forest plot showing meta-analysis of death rates per day in cohort studies according to acuity

MIX, combined emergency and elective.

SMC-TINCO registry, Samsung Medical Center Troponin in Non cardiac Operation registry.

cent c.i. 0.15–0.39). Acuity did not appear to impact mortality as subgroup differences were not statistically significant (P = 0.14). However, these results may not be representative as it was not possible to differentiate between elective and emergency surgery cases in most included studies with only one study focusing specifically on emergency surgery³¹.

MACE was also highlighted as a major complication following MINS by this review, with an incidence of 21 per cent (95 per cent c.i. 12–34 per cent) at 1 year. A non-linear increase in event rate is also noted between 6 months to 1 year and beyond 2 years. This supports the premise of a standardized postoperative follow-up interval, which will help to improve the fidelity of reporting complications associated with MINS and guide future risk reduction strategies.

The meta-analysis demonstrated that the relationship between surgical acuity and MACE is statistically significant. The elective

population had lower rates of MACE events (0.02 per day 95 per cent c.i. 0.01-0.07), compared with a mixed acuity group which included emergency surgeries (0.13 per day 95 per cent c.i. 0.03-0.68) and that this difference was statistically significant (P < 0.01). Unfortunately, there was no eligible study available which focused solely on emergency surgery and reported MACE outcomes. Despite this, the results suggest that emergency surgery may have an impact on MACE events post-MINS but further research focusing specifically on emergency surgery is required. This could be possible with clearer reporting and analysis of acuity subgroups in future studies. Improved reporting of types of surgery included in studies would also be beneficial in monitoring outcomes as inadequate numbers of studies were found to allow meta-analysis for MACE components in urology, orthopaedic and thoracic surgery. Whilst the meta-analysis has been carried out for the non-cardiac subgroup, this may have little clinical significance as

Study	Events	Time)	Incidence rate	Rate	95% c.i.	Weight (%)
Acuity = not specified Devereaux <i>et al.</i> ¹⁵	110	730			0.15	(0.13, 0.18)	42.1
Acuity = emergency Chong <i>et al.</i> ³²	6	365			0.02	(0.01, 0.04)	38.5
Acuity = elective Toda <i>et al.</i> ⁵⁸	0	30	-		0.02	(0.00, 0.27)	19.3
Random-effects model Heterogeneity: $\tau^2 = 1.6780$; $P < 0.0$ Test for subgroup differences: $\chi^2_2 =$	01;	P < 0.0	1) 0	0.00 0.01 0.15 0.20 0.25	0.04	(0.01, 0.22)	100.0

Fig. 4 Forest plot showing meta-analysis of control arms demonstrating deaths per day

Study	Events	Time	Incidence rate	Rate	95% c.i.	Weight (%)
Acuity = MIX						
Sazgary et al.56	90	365		0.25	(0.20, 0.30)	11.7
Mol et al.49	134	365		0.37	(0.31, 0.43)	11.7
Yuan <i>et al.</i> 64	9	365	e	0.02	(0.01, 0.05)	11.1
Random-effects model				0.13	(0.03, 0.68)	34.5
Heterogeneity: $\tau^2 = 2.0167$; $P < 0.01$; I^2	= 97%					
Acuity = not specified						
Kier <i>et al.</i> ⁴⁶	6	90		0.07	(0.03, 0.15)	10.8
Szczeklik <i>et al.</i> 57	21	365	i n	0.06	(0.04, 0.09)	11.5
Random-effects model			►	0.06	(0.04, 0.09)	22.2
Heterogeneity: $\tau^2 = 0$; $P = 0.75$; $I^2 = 0\%$						
Acuity = elective						
Pereira–Macedo et al.53	11	1550 🛨		0.01	(0.00, 0.01)	11.2
Yu <i>et al.</i> 63	6	365 📘		0.02	(0.01, 0.04)	10.8
Ali <i>et al.</i> ²⁸	9	571 🔤		0.02	(0.01, 0.03)	11.1
Gonzalez–Tallada <i>et al</i> .36	4	30		0.13	(0.05, 0.36)	10.3
Random-effects model		•	▶	0.02	(0.01, 0.07)	43.3
Heterogeneity: $\tau^2 = 1.3275$; <i>P</i> < 0.01; <i>I</i> ²	= 88%					
Random-effects model				0.05	(0.02, 0.13)	100.0
Heterogeneity: $\tau^2 = 1.7705$; <i>P</i> < 0.01; <i>I</i> ²	= 98%		0.1 0.2 0.3 0.4 0.5 0.6			

Fig. 5 Forest plot showing meta-analysis of cohort studies and MACE rate per day according to acuity

MACE, major adverse cardiac events; MIX, combined emergency and elective.

the subgroup likely contains high heterogeneity within its case mix. Investigating specific risks in subspecialties would be beneficial in understanding different risk profiles for differing types of surgery and may allow improved patient counselling and tailored management strategies in the future.

As this review included studies from 1997 to 2021, a diverse collection of acceptable diagnostic criteria for MINS was observed. For example, inconsistencies in sampling frequency can lead to variations in the incidence of MINS captured by studies and shorter duration of monitoring and troponin sampling could lead to events being missed. Another issue highlighted by Smilowitz *et al.* (2019)¹⁸ was inappropriately labelling unrelated cardiac events as being precipitated by surgery if the duration of sampling was too long¹⁸.

Inconsistencies around troponin assays can also lead to inaccurate diagnosis of MINS and therefore outcome reporting. The VISION (Vascular events In non-cardiac Surgery patIents cohOrt evaluatioN) study in 2014 has attempted to delineate the diagnostic criteria of MINS and have suggested a cut-off value for troponin T². The present review has found that this criterion is not universally followed. Interestingly, this meta-analysis has shown that the use of high-sensitivity troponin for the diagnosis of MINS was associated with lower mortality and MACE rates. Potential confounders are that non-high-sensitivity troponin studies may be older with different standards of care to current practice. Alternatively, these results may imply that high-sensitivity troponin is too sensitive and so a higher threshold may be required to reach clinical significance. Notably, heterogeneity within the groups was high and further research specifically focusing on this area would be beneficial.

Furthermore, a wide variety of MACE definitions were also observed from the included studies. This is an important but common issue in cardiovascular research, which has been highlighted by a systematic review in 2021¹⁶. Inconsistency in definition was also seen within the studies reporting congestive cardiac failure as an outcome measure^{2,28,31,32,37,48,53,56,58,64}.

Study	Events	Time	Incidence Rate	Rate	95% c.i.	Weight (%)
Acuity = not specified Devereaux <i>et al.</i> ¹⁵	133	730	-	0.18	(0.15, 0.22)	34.0
Acuity = emergency Chong <i>et al</i> . ³²	8	365 +		0.02	(0.01, 0.04)	32.6
Acuity = elective Toda <i>et al.</i> ⁵⁸	19	30		- 0.63	(0.40, 0.99)	33.4
Random-effects model Heterogeneity: $\tau^2 = 2.7656$; $P < 0.01$; $I^2 = 9$ Test for subgroup differences: $\chi_2^2 = 65.09$, $Z_2^2 = 65.09$	97% 2 d.f., <i>P</i> < 0.	-	0.2 0.4 0.6 0.8	0.14	(0.02, 0.93)	100.0

Fig. 6 Forest plot showing meta-analysis of control arms and MACE rate per day according to acuity

MACE, major adverse cardiac events.

Study	Events Total	Proportion	95% c.i.
High-sensitivity troponin used = No Oscarsson <i>et al.</i> ⁵¹ Kim <i>et al.</i> ⁴² Kim <i>et al.</i> ⁴⁴ – data from SMC-TINCO registry Yu <i>et al.</i> ⁶³ Canbolat <i>et al.</i> ³⁰ Reed <i>et al.</i> ⁵⁴ van Waes <i>et al.</i> ⁶⁰ Rostagno <i>et al.</i> ⁵⁵ van Waes <i>et al.</i> ⁶¹ Kertai <i>et al.</i> ⁴¹ Auroy <i>et al.</i> ²⁹ Hobbs <i>et al.</i> ³⁹ Filipovic <i>et al.</i> ³³ Ali <i>et al.</i> ²⁸ Botto <i>et al.</i> ² Kim <i>et al.</i> ⁴³ Kisten and Biccard <i>et al.</i> ⁴⁵ Random-effects model Heterogeneity: $\tau^2 = 0.5674$; $P < 0.01$; $l^2 = 94\%$	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	$\begin{array}{c} 0.32\\ 0.08\\ 0.19\\ 0.29\\ 0.06\\ 0.42\\ 0.25\\ 0.38\\ 0.24\\ 0.41\\ 0.27\\ 0.27\\ 0.27\\ 0.44\\ 0.10\\ 0.10\\ 0.10\\ 0.24\\ 0.54\\ 0.20\\ 0.24\\ \end{array}$	$\begin{array}{c} (0.20, \ 0.46) \\ (0.05, \ 0.12) \\ (0.18, \ 0.20) \\ (0.15, \ 0.46) \\ (0.22, \ 0.29) \\ (0.28, \ 0.49) \\ (0.28, \ 0.49) \\ (0.28, \ 0.49) \\ (0.28, \ 0.55) \\ (0.06, \ 0.61) \\ (0.26, \ 0.65) \\ (0.01, \ 0.32) \\ (0.08, \ 0.12) \\ (0.28, \ 0.47) \\ (0.28, \ 0.32) \\ (0.44, \ 0.65) \\ (0.08, \ 0.37) \\ (0.18, \ 0.32) \end{array}$
High-sensitivity troponin used = Yes Vasireddi <i>et al.</i> ⁶² Mol <i>et al.</i> ⁴⁹ Pereira-Macedo <i>et al.</i> ⁵³ Lee <i>et al.</i> ⁴⁷ Chong <i>et al.</i> ³¹ Szczeklik <i>et al.</i> ¹⁵ Yuan <i>et al.</i> ⁶⁴ Hallqvist <i>et al.</i> ³⁸ Gonzalez-Tallada <i>et al.</i> ³⁶ George <i>et al.</i> ³⁵ Vacheron <i>et al.</i> ⁵⁹ Random-effects model Heterogeneity: τ^2 = 0.8571; <i>P</i> < 0.01; <i>I</i> ² = 85%	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	0.28 0.18 0.59 0.11 0.37 0.25 0.28 0.07 0.00 0.12 0.25 0.19	$\begin{array}{c} (0.22,0.35)\\ (0.16,0.20)\\ (0.33,0.82)\\ (0.06,0.17)\\ (0.24,0.51)\\ (0.24,0.51)\\ (0.14,0.37)\\ (0.14,0.45)\\ (0.02,0.14)\\ (0.00,0.07)\\ (0.07,0.17)\\ (0.22,0.29)\\ (0.11,0.29) \end{array}$
Random-effects model Heterogeneity: $\tau^2 = 0.6677$; $P < 0.01$; $I^2 = 92\%$		0.22	(0.17, 0.28)

Fig. 7 Forest plot showing meta-analysis of death in control arms according to assessment of troponin

SMC-TINCO registry, Samsung Medical Center Troponin in Non cardiac Operation registry.

This study is not without limitations. The definition of MINS varies across the literature and reporting of MACE is inconsistent, which probably contributed to the high heterogeneity observed between the included studies. The meta-analysis was limited by the reporting of individual MACE outcomes within published studies which may impact captured event rates. A limited number of studies specifically focusing on defined subgroups, such as surgical acuity and type of surgery, could also potentially lead to increased granularity with comparisons between the subgroups. For example a large proportion of the studies were labelled as 'not specified' which did not allow comparisons to be made with other

groups. This resulted in only one study focusing on emergency surgery being identified. Similarly, in the surgical type subgroups, only single studies were found to represent thoracic and urological surgery. The meta-analysis of control arms of RCTs was also limited—only three eligible studies were found, which led to high heterogeneity. This high heterogeneity may explain the discordance between the rates demonstrated by meta-analysis in the cohort studies as well as the apparent reduction in MACE and myocardial infarction event rates through time.

The study by Yuan *et al.*⁶⁴ incorrectly used mg/l as a unit of measurement for troponin I which could be due to a printing error.

Additionally, none of the studies including congestive cardiac failure as an outcome^{2,28,31,32,37,48,53,56,58,64} differentiated between heart failure with preserved ejection fraction and heart failure with reduced ejection fraction, potentially limiting this analysis.

Despite this, the systematic review and meta-analysis included a wide sample and was conducted in line with PRIMSA and MOOSE guidance^{19,21} and was prospectively registered. These results provide a pragmatic overview of the long-term sequelae of MINS and the range of events associated with it. By only including patients who have a diagnosis, this review was able to specifically focus on MINS-associated outcomes beyond 30 days. By collating the different accepted diagnostic criteria, the findings clearly demonstrate the lack of consistency and standardization in the diagnosis of MINS.

This review has demonstrated significant MACE rates and high long-term mortality associated with MINS. However, the reporting of MACE is inconsistent and the diagnostic criteria for MINS is wide-ranging and lacks uniformity. Future research should aim to establish consistent definitions and sampling frames to diagnose MINS, as well as ensuring key MACE outcomes are reported individually and as an aggregated event count. Researchers should ensure they monitor outcomes to at least 1-year after surgery.

Studies have shown that MINS may be preventable⁶⁸ and it may be possible to mitigate the sequelae of MINS^{15,69}. It is imperative that MINS is explored as a modifiable outcome in patients undergoing non-cardiac surgery, particularly in the emergency setting. The initial identification of MINS patients, who are at a higher risk of future MACE, facilitates the development of follow-up as well as secondary prevention strategies. Clinicians might consider whether they wish to routinely assess for MINS in perioperative practice. Recent European Society of Cardiology (ESC) guidelines⁷⁰ recommend routine perioperative troponin screening for at-risk patients undergoing non-cardiac surgery. This highlights the increasing recognition of MINS. Sadly, they do not offer guidance on the management of MINS in this setting, and this represents a major research gap.

Funding

The authors received funding from the University of Sheffield Institutional Open Access Fund to allow open access publication of the article.

Disclosure

The authors declare no conflict of interest.

Supplementary material

Supplementary material is available at BJS Open online.

Data availability

All data is included.

References

- Ramsay G, Wohlgemut JM, Bekheit M, Watson AJM, Jansen JO. Causes of death after emergency general surgical admission: population cohort study of mortality. BJS Open 2021;5:zrab021
- 2. Botto F, Alonso-Coello P, Chan MT, Villar JC, Xavier D, Srinathan S et al. Myocardial injury after noncardiac surgery: a large,

international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes. *Anesthesiology* 2014;**120**:564–578

- 3. Domienik-Karłowicz J, Kupczyńska K, Michalski B, Kapłon-Cieślicka A, Darocha S, Dobrowolski P et al. Fourth universal definition of myocardial infarction. Selected messages from the European Society of Cardiology document and lessons learned from the new guidelines on ST-segment elevation myocardial infarction and non-ST-segment elevation-acute coronary syndrome. Cardiol J 2021;28:195–201
- Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J 2019;40:237–269
- Vascular Events In Noncardiac Surgery Patients Cohort Evaluation (VISION) Study Investigators; Devereaux PJ, Chan MTV, Alonso-Coello P, Walsh M, Berwanger O et al. Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery. JAMA 2012; 307:2295–2304
- Devereaux PJ, Szczeklik W. Myocardial injury after non-cardiac surgery: diagnosis and management. Eur Heart J 2019;41: 3083–3091
- Writing Committee for the VISION Study Investigators; Devereaux PJ, Biccard BM, Sigamani A, Xavier D, Chan MTV et al. Association of postoperative high-sensitivity troponin levels with myocardial injury and 30-day mortality among patients undergoing noncardiac surgery. JAMA 2017;317: 1642–1651
- McIlroy DR, Chan MTV, Wallace SK, Symons JA, Koo EGY, Chu LCY et al. Automated preoperative assessment of endothelial dysfunction and risk stratification for perioperative myocardial injury in patients undergoing non-cardiac surgery. Br J Anaesth 2014;112:47–56
- Ekeloef S, Oreskov JO, Falkenberg A, Burcharth J, Schou-Pedersen AMV, Lykkesfeldt J et al. Endothelial dysfunction and myocardial injury after major emergency abdominal surgery: a prospective cohort study. BMC Anesthesiol 2020;20:67
- May SM, Reyes A, Martir G, Reynolds J, Paredes LG, Karmali S et al. Acquired loss of cardiac vagal activity is associated with myocardial injury in patients undergoing noncardiac surgery: prospective observational mechanistic cohort study. Br J Anaesth 2019;**123**:758–767
- Abbott TEF, Pearse RM, Cuthbertson BH, Wijeysundera DN, Ackland GL; METS study investigators. Cardiac vagal dysfunction and myocardial injury after non-cardiac surgery: a planned secondary analysis of the measurement of exercise tolerance before surgery study. Br J Anaesth 2019; 122:188–197
- Ruetzler K, Khanna AK, Sessler DI. Myocardial injury after noncardiac surgery: preoperative, intraoperative, and postoperative aspects, implications, and directions. Anesth Analg 2020;131:173–186
- Ekeloef S, Bjerrum E, Kristiansen P, Wahlstrøm K, Burcharth J, Gögenur I. The risk of post-operative myocardial injury after major emergency abdominal surgery: a retrospective cohort study. Acta Anaesthesiol Scand 2020;64:1073–1081
- Shah ASV, McAllister DA, Mills R, Lee KK, Churchhouse AMD, Fleming KM et al. Sensitive troponin assay and the classification of myocardial infarction. Am J Med 2015;128: 493–501.e3
- Devereaux PJ, Duceppe E, Guyatt G, Tandon V, Rodseth R, Biccard BM et al. Dabigatran in patients with myocardial injury

after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial. *Lancet* 2018;**391**: 2325–2334

- Bosco E, Hsueh L, McConeghy KW, Gravenstein S, Saade E. Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review. BMC Med Res Methodol 2021;21:241
- 17. Puelacher C, Lurati Buse G, Seeberger D, Sazgary L, Marbot S, Lampart A et al. Perioperative myocardial injury after noncardiac surgery: incidence, mortality, and characterization. *Circulation* 2018;**137**:1221–1232
- Smilowitz NR, Redel-Traub G, Hausvater A, Armanious A, Nicholson J, Puelacher C et al. Myocardial injury after noncardiac surgery: a systematic review and meta-analysis. Cardiol Rev 2019;27:267–273
- PRISMA. http://www.prisma-statement.org/ (accessed 13 June 2022)
- Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3, https://training.cochrane.org/ handbook/current (accessed 17 July 2022)
- Brooke BS, Schwartz TA, Pawlik TM. MOOSE reporting guidelines for meta-analyses of observational studies. JAMA Surg 2021;156:787–788
- Beattie WS, Karkouti K, Tait G, Steel A, Yip P, McCluskey S et al. Use of clinically based troponin underestimates the cardiac injury in non-cardiac surgery: a single-centre cohort study in 51,701 consecutive patients. Can J Anaesth 2012;59:1013–1022
- 23. Rayyan. Rayyan Intelligent Systematic Review. https://www.rayyan.ai/ (accessed 24 June 2022)
- 24. Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. *Evid Based Ment* Health 2019;**22**:153–160
- Cochrane. QUIPS Tool. http://methods.cochrane.org/sites/ methods.cochrane.org.prognosis/files/uploads/QUIPS%20tool. pdf (accessed 17 March 2023)
- 26. Grooten WJA, Tseli E, Äng BO, Boersma K, Stålnacke B-M, Gerdle B et al. Elaborating on the assessment of the risk of bias in prognostic studies in pain rehabilitation using QUIPS-aspects of interrater agreement. Diagn Progn Res 2019;**3**:5
- 27. Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and open synthesis. *Campbell* Syst Rev 2022;**18**:e1230
- Ali ZA, Callaghan CJ, Ali AA, Sheikh AY, Akhtar A, Pavlovic A et al. Perioperative myocardial injury after elective open abdominal aortic aneurysm repair predicts outcome. Eur J Vasc Endovasc Surg 2008;35:413–419
- Ausset S, Auroy Y, Lambert E, Vest P, Plotton C, Rigal S et al. Cardiac troponin I release after hip surgery correlates with poor long-term cardiac outcome. Eur J Anaesthesiol 2008;25: 158–164
- Canbolat IP, Adali G, Akdeniz CS, Bozkurt B, Ferah O, Bulutcu F et al. Postoperative myocardial injury does not predict early and 1-year mortality after living donor liver transplantation. Transplant Proc 2019;51:2478–2481
- Chong CP, Lam QT, Ryan JE, Sinnappu RN, Lim WK. Incidence of post-operative troponin I rises and 1-year mortality after emergency orthopaedic surgery in older patients. Age Ageing 2009;38:168–174
- Chong CP, van Gaal WJ, Ryan JE, Profitis K, Savige J, Lim WK. Does cardiology intervention improve mortality for post-operative troponin elevations after emergency

orthopaedic-geriatric surgery? A randomised controlled study. Injury 2012;**43**:1193–1198

- 33. Filipovic M, Jeger R, Probst C, Girard T, Pfisterer M, Gürke L et al. Heart rate variability and cardiac troponin I are incremental and independent predictors of one-year all-cause mortality after major noncardiac surgery in patients at risk of coronary artery disease. J Am Coll Cardiol 2003;42:1767–1776
- Moralar DG, Balkan B, Moralar DG. Myocardial injury after noncardiac surgery in geriatric patients. Turk J Geriatr 2021;24: 351-358
- 35. George R, Menon VP, Edathadathil F, Balachandran S, Moni M, Sathyapalan D et al. Myocardial injury after noncardiac surgery-incidence and predictors from a prospective observational cohort study at an Indian tertiary care centre. *Medicine (Baltimore)* 2018;97:e0402
- 36. González-Tallada A, Borrell-Vega J, Coronado C, Morales P, de Miguel M, Ferreira-González I et al. Myocardial injury after noncardiac surgery: incidence, predictive factors, and outcome in high-risk patients undergoing thoracic surgery: an observational study. J Cardiothorac Vasc Anesth 2020;**34**:426–432
- Gouda P, Wang X, McGillion M, Graham MM. Underutilization of perioperative screening for cardiovascular events after noncardiac surgery in Alberta. Can J Cardiol 2021;37:57–65
- Hallqvist L, Mårtensson J, Granath F, Sahlén A, Bell M. Intraoperative hypotension is associated with myocardial damage in noncardiac surgery: an observational study. Eur J Anaesthesiol 2016;33:450–456
- Hobbs SD, Yapanis M, Burns PJ, Wilmink AB, Bradbury AW, Adam DJ. Peri-operative myocardial injury in patients undergoing surgery for critical limb ischaemia. Eur J Vasc Endovasc Surg 2005;29:301–304
- 40. Jackson MWP, Hammonds M, Cunningham N, Austin D, Swanson N, de Belder M et al. Postoperative high-sensitivity troponin monitoring following noncardiac surgery: evaluating the effect on mortality of associated perioperative clinical events. J Anesthes Perioper Med 2018;5:281–292
- Kertai MD, Boersma E, Klein J, van Urk H, Bax JJ, Poldermans D. Long-term prognostic value of asymptomatic cardiac troponin T elevations in patients after major vascular surgery. Eur J Vasc Endovasc Surg 2004;28:59–66
- Kim LJ, Martinez EA, Faraday N, Dorman T, Fleisher LA, Perler BA et al. Cardiac troponin I predicts short-term mortality in vascular surgery patients. Circulation 2002;106:2366–2371
- Kim M, Son M, Lee DH, Park K, Park T-H. Troponin-I level after major noncardiac surgery and its association with long-term mortality. Int Heart J 2016;57:278–284
- 44. Kim S, Park J, Kwon J-H, Oh AR, Gook J, Yang K et al. The Charlson Comorbidity index is associated with risk of 30-day mortality in patients with myocardial injury after non-cardiac surgery. Sci Rep 2021;**11**:18933
- Kisten T, Biccard BM. Incidence and hospital mortality of vascular surgery patients with perioperative myocardial infarction (PMI) or myocardial injury after non-cardiac surgery (MINS). South African J Anaesth Analg 2017;23:64–68
- Kler A, Dave M, Baltatzis M Satyadas T. Elevation of high-sensitive troponin T predicts mortality after open pancreaticoduodenectomy. World J Surg 2021;45:1913–1920
- Lee S-H, Park MS, Song YB, Park J, Kim J, Lee SM et al. Perioperative myocardial injury in revascularized coronary patients who undergo noncardiac surgery. PLoS One 2019;14: e0219043
- 48. Lee S-H, Park J, Lee J-H, Min JJ, Hong KY, Cho H et al. Comparison of pre- and postoperative myocardial injuries on mortality after

non-cardiac surgery: a retrospective analysis using an inverse probability weighting adjustment. Sci Rep 2020;**10**:21050

- Mol KHJM, Hoeks SE, Liem VGB, Stolker RJ, van Lier F. Postoperative troponin release is associated with major adverse cardiovascular events in the first year after noncardiac surgery. Int J Cardiol 2019;280:8–13
- Oberweis BS, Smilowitz NR, Nukala S, Rosenberg A, Xu J, Stuchin S et al. Relation of perioperative elevation of troponin to long-term mortality after orthopedic surgery. Am J Cardiol 2015;115:1643–1648
- 51. Oscarsson A, Eintrei C, Anskar S, Engdahl O, Fagerstrom L, Blomqvist P et al. Troponin T-values provide long-term prognosis in elderly patients undergoing non-cardiac surgery. Acta Anaesthesiol Scand 2004;48:1071–1079
- Pereira-Macedo J, Rocha-Neves JP, Dias-Neto MF, Andrade JPV. Prognostic effect of troponin elevation in patients undergoing carotid endarterectomy with regional anesthesia—a prospective study. Int J Surg 2019;**71**:66–71
- Pereira-Macedo J, Machado N, Pereira-Neves A, Ferreira V, Oliveira-Pinto J, Dias-Neto M et al. Myocardial injury after aortoiliac revascularization for extensive disease: a survival analysis. Turk Gogus Kalp Damar Cerrahisi Derg 2020;28:426–434
- Reed GW, Horr S, Young L, Clevenger J, Malik U, Ellis SG et al. Associations between cardiac troponin, mechanism of myocardial injury, and long-term mortality after noncardiac vascular surgery. J Am Heart Assoc 2017;6:e005672
- 55. Rostagno C, Peris A, Polidori GL, Ranalli C, Cartei A, Civinini R et al. Perioperative myocardial infarction in elderly patients with hip fracture. Is there a role for early coronary angiography? Int J Cardiol 2019;284:1–5
- Sazgary L, Puelacher C, Buse GL, Glarner N, Lampart A, Bolliger D et al. Incidence of major adverse cardiac events following non-cardiac surgery. Eur Heart J Acute Cardiovasc Care 2021;10:550–558
- 57. Szczeklik W, Krzanowski M, Maga P, Partyka Ł, Kościelniak J, Kaczmarczyk P et al. Myocardial injury after endovascular revascularization in critical limb ischemia predicts 1-year mortality: a prospective observational cohort study. Clin Res Cardiol 2018;107:319–328
- Toda H, Nakamura K, Shimizu K, Ejiri K, Iwano T, Miyoshi T et al. Effects of bisoprolol transdermal patches for prevention of perioperative myocardial injury in high-risk patients undergoing non-cardiac surgery—multicenter randomized controlled study. Circ J 2020;84:642–649
- 59. Vacheron C-H, Hentzen J, Fauvernier M, Fessy M, Chaudier P, Landel V. Association between short-, intermediate-, and long-term mortality and myocardial injury after noncardiac surgery after hip fracture surgery: a retrospective cohort. *Anesth Analg* 2021;**133**:915–923

- 60. van Waes JAR, Grobben RB, Nathoe HM, Kemperman H, de Borst GJ, Peelen LM et al. One-year mortality, causes of death, and cardiac interventions in patients with postoperative myocardial injury. Anesth Analg 2016;**123**:29–37
- 61. van Waes JAR, Peelen LM, Kemperman H, Grobben RB, Nathoe HM, van Klei WA. Kinetics of troponin I in patients with myocardial injury after noncardiac surgery. *Clin Chem Lab Med* 2017;**55**:586–594
- 62. Vasireddi SK, Pivato E, Soltero-Mariscal E, Chava R, James LO, Gunzler D et al. Postoperative myocardial injury in patients classified as low risk preoperatively is associated with a particularly increased risk of long-term mortality after noncardiac surgery. J Am Heart Assoc 2021;**10**:e019379
- Yu J, Lim B, Lee Y, Park J-Y, Hong B, Hwang J-H et al. Risk factors and outcomes of myocardial injury after non-cardiac surgery in high-risk patients who underwent radical cystectomy. *Medicine* (Baltimore) 2020;99:e22893
- 64. Yuan K, Chen H-L, Li W-D, Cui Z-M. Perioperative elevation of troponin I predicts survival after orthopaedic surgery in older patients with fracture. Int J Gerontol 2018
- Lopez-Jimenez F, Goldman L, Sacks DB, Thomas EJ, Johnson PA, Cook EF et al. Prognostic value of cardiac troponin T after noncardiac surgery: 6-month follow-up data. J Am Coll Cardiol 1997;29:1241–1245
- 66. Park J, Kim J, Lee S-H, Lee JH, Min JJ, Kwon JH et al. Postoperative statin treatment may be associated with improved mortality in patients with myocardial injury after noncardiac surgery. Sci Rep 2020;10:11616
- Park J, Yang K, Lee S-H, Lee JH, Min JJ, Kwon JH et al. Comparison of acute and chronic myocardial injury in noncardiac surgical patients. PLoS One 2020;15:e0234776
- Ekeloef S, Homilius M, Stilling M, Ekeloef P, Koyuncu S, Münster AB et al. The effect of remote ischaemic preconditioning on myocardial injury in emergency hip fracture surgery (PIXIE trial): phase II randomised clinical trial. BMJ 2019;367:16395
- Lamidi S, Baker DM, Wilson MJ, Lee MJ. Remote ischemic preconditioning in non-cardiac surgery: a systematic review and meta-analysis. J Surg Res 2021;261–273
- 70. Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M, Barbato E et al. 2022 ESC guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery: developed by the task force for cardiovascular assessment and management of patients undergoing non-cardiac surgery of the European Society of Cardiology (ESC) Endorsed by the European Society of Anaesthesiology and Intensive Care (ESAIC). Eur Heart J 2022; 43:3826–3924